JP6138928B2 - 医薬に使用されるｎｏｔｃｈシグナル伝達経路及び分泌の阻害物質 - Google Patents

医薬に使用されるｎｏｔｃｈシグナル伝達経路及び分泌の阻害物質 Download PDF

Info

Publication number
JP6138928B2
JP6138928B2 JP2015514538A JP2015514538A JP6138928B2 JP 6138928 B2 JP6138928 B2 JP 6138928B2 JP 2015514538 A JP2015514538 A JP 2015514538A JP 2015514538 A JP2015514538 A JP 2015514538A JP 6138928 B2 JP6138928 B2 JP 6138928B2
Authority
JP
Japan
Prior art keywords
fli
cancer
cells
compounds
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015514538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520770A (ja
JP2015520770A5 (enExample
Inventor
ケテル，クリストフ
クレーマー，アンドレアス
Original Assignee
ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー．ファウ．（エフエルイー）
ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー．ファウ．（エフエルイー）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー．ファウ．（エフエルイー）, ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー．ファウ．（エフエルイー） filed Critical ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー．ファウ．（エフエルイー）
Publication of JP2015520770A publication Critical patent/JP2015520770A/ja
Publication of JP2015520770A5 publication Critical patent/JP2015520770A5/ja
Application granted granted Critical
Publication of JP6138928B2 publication Critical patent/JP6138928B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015514538A 2012-06-01 2013-06-03 医薬に使用されるｎｏｔｃｈシグナル伝達経路及び分泌の阻害物質 Expired - Fee Related JP6138928B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12170403.5 2012-06-01
EP12170403 2012-06-01
PCT/EP2013/061363 WO2013178821A1 (en) 2012-06-01 2013-06-03 Inhibitors of the notch signalling pathway and secretion for use in medicine

Publications (3)

Publication Number Publication Date
JP2015520770A JP2015520770A (ja) 2015-07-23
JP2015520770A5 JP2015520770A5 (enExample) 2015-12-17
JP6138928B2 true JP6138928B2 (ja) 2017-05-31

Family

ID=48577739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514538A Expired - Fee Related JP6138928B2 (ja) 2012-06-01 2013-06-03 医薬に使用されるｎｏｔｃｈシグナル伝達経路及び分泌の阻害物質

Country Status (5)

Country Link
US (1) US9828344B2 (enExample)
EP (1) EP2854809B1 (enExample)
JP (1) JP6138928B2 (enExample)
HK (1) HK1204928A1 (enExample)
WO (1) WO2013178821A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
US10071087B2 (en) 2014-07-22 2018-09-11 Bioventures, Llc Compositions and methods for selectively depleting senescent cells
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
US10807977B2 (en) 2016-04-21 2020-10-20 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
IT201600132360A1 (it) 2016-12-29 2018-06-29 Univ Degli Studi Roma La Sapienza Inibitori di notch per uso nel trattamento della leucemia linfoblastica acuta a cellule t
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
JP2022504265A (ja) 2018-10-02 2022-01-13 フリークエンシー セラピューティクス インコーポレイテッド 耳治療薬に関する医薬組成物及び方法
US20220175776A1 (en) 2019-04-08 2022-06-09 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
CA3158905A1 (en) * 2019-12-09 2021-06-17 Wisconsin Alumni Research Foundation Chemical cocktail for inducing senescence in human neurons to promote disease modeling and drug discovery
US20230183215A1 (en) * 2020-05-21 2023-06-15 Stemsynergy Therapeutics, Inc. Notch Inhibitors and Uses Thereof
CN116710455A (zh) * 2021-01-20 2023-09-05 株式会社棱镜生物实验室 新型双环化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2003148A1 (de) * 1970-01-24 1971-07-29 Bayer Ag Neue 1,4-Dihydropyridinderivate
DE2003146A1 (de) 1970-01-24 1971-07-29 Bayer Ag Neue 1,4-Dihydropyridinderivate
US7244757B2 (en) * 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2006074419A2 (en) 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
WO2008070875A2 (en) * 2006-12-08 2008-06-12 Roskamp Research Llc Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
WO2009006580A1 (en) 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
US8119640B2 (en) * 2008-02-12 2012-02-21 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog pathway antagonists methods of use
EP2348855A4 (en) * 2008-09-17 2013-01-09 Burnham Inst Medical Research Small-molecule bonds for stem cell differentiation
US20110281356A1 (en) * 2008-09-17 2011-11-17 Human Biomolecular Research Institute Compounds for stem cell differentiation
AP2012006277A0 (en) 2009-10-23 2012-06-30 Health Research Inc Method for treating androgen receptor positive cancers.
JP2013542245A (ja) 2010-11-11 2013-11-21 レッドエックス ファーマ リミテッド 薬物誘導体

Also Published As

Publication number Publication date
EP2854809A1 (en) 2015-04-08
HK1204928A1 (en) 2015-12-11
WO2013178821A1 (en) 2013-12-05
US20150175548A1 (en) 2015-06-25
US9828344B2 (en) 2017-11-28
JP2015520770A (ja) 2015-07-23
EP2854809B1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
JP6138928B2 (ja) 医薬に使用されるｎｏｔｃｈシグナル伝達経路及び分泌の阻害物質
Gallagher et al. Ceapins are a new class of unfolded protein response inhibitors, selectively targeting the ATF6α branch
Boselli et al. An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons
Krämer et al. Small molecules intercept Notch signaling and the early secretory pathway
Yin et al. Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS
US10065951B2 (en) Small molecule transcription modulators of bromodomains
US20240142437A1 (en) Methods to prevent teratogenicity of imid like molecules and imid based degraders/protacs
WO2008016659A2 (en) Agents for treating neurodegenerative diseases
Pischedda et al. LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation
Lee et al. Discovery of 5-(2′, 4′-difluorophenyl)-salicylanilides as new inhibitors of receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis
EP3280404B1 (en) Methods for selecting phosphatase selective and non-selective phosphatase inhibitors
Estrada et al. New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition
Roell et al. Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists
Makhaeva et al. Aminoadamantane conjugates with carbazole derivatives as potential multitarget agents for the treatment of Alzheimer’s disease. Effect of the spacer structure
Huang et al. Inhibition of p38 mitogen–activated protein kinase ameliorates HAP40 depletion–induced toxicity and proteasomal defect in Huntington’s disease model
Carling et al. Multiparameter phenotypic screening for endogenous TFEB and TFE3 translocation identifies novel chemical series modulating lysosome function
Chierrito et al. Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors
Cho et al. CARM1 regulates tubulin autoregulation through PI3KC2α R175 methylation
Casalino et al. A novel high-throughput screening strategy for targeting alpha-synuclein and other long-lived proteins
Kravchenko et al. Synthesis, molecular docking, ADMET study and in vitro pharmacological research of 7-(2-chlorophenyl)-4-(4-methylthiazol-5-yl)-4, 6, 7, 8-tetrahydroquinoline-2, 5 (1H, 3H)-dione as a promising non-opioid analgesic drug
Bott et al. The polyglutamine-expanded androgen receptor responsible for spinal and bulbar muscular atrophy inhibits the APC/CCdh1 ubiquitin ligase complex
Köhler et al. Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities
US20070027164A1 (en) Agents for treating neurodegenerative diseases
WO2023092133A1 (en) Stereoselective covalent ligands for oncogenic and immunological proteins
US20240050440A1 (en) Therapeutic targets and agents for the treatment of triosephosphate isomerase (tpi) deficiency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170417

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170426

R150 Certificate of patent or registration of utility model

Ref document number: 6138928

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees